Ameriprise Financial Inc. grew its position in shares of Puma Biotechnology Inc (NASDAQ:PBYI) by 0.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 165,547 shares of the biopharmaceutical company’s stock after purchasing an additional 1,443 shares during the period. Ameriprise Financial Inc. owned about 0.44% of Puma Biotechnology worth $19,824,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently modified their holdings of the business. Bank of Montreal Can increased its holdings in Puma Biotechnology by 1.8% during the 2nd quarter. Bank of Montreal Can now owns 5,351 shares of the biopharmaceutical company’s stock valued at $468,000 after purchasing an additional 97 shares during the period. Ameritas Investment Partners Inc. grew its holdings in shares of Puma Biotechnology by 5.9% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,522 shares of the biopharmaceutical company’s stock worth $220,000 after acquiring an additional 140 shares during the period. Rhumbline Advisers boosted its position in shares of Puma Biotechnology by 0.8% in the 2nd quarter. Rhumbline Advisers now owns 33,733 shares of the biopharmaceutical company’s stock worth $2,948,000 after purchasing an additional 271 shares in the last quarter. The Manufacturers Life Insurance Company boosted its position in shares of Puma Biotechnology by 2.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 22,299 shares of the biopharmaceutical company’s stock worth $1,950,000 after purchasing an additional 437 shares in the last quarter. Finally, Parametric Portfolio Associates LLC lifted its position in Puma Biotechnology by 13.5% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 7,844 shares of the biopharmaceutical company’s stock valued at $686,000 after acquiring an additional 936 shares in the last quarter. 96.00% of the stock is owned by hedge funds and other institutional investors.
In related news, insider Charles R. Eyler sold 1,322 shares of Puma Biotechnology stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $105.46, for a total transaction of $139,418.12. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 21.10% of the company’s stock.
Shares of Puma Biotechnology Inc (NASDAQ PBYI) traded down $6.20 during midday trading on Tuesday, reaching $92.65. 985,820 shares of the company’s stock traded hands, compared to its average volume of 758,500. The company has a market capitalization of $3,480.00, a P/E ratio of -11.31 and a beta of 0.73. Puma Biotechnology Inc has a twelve month low of $28.35 and a twelve month high of $136.90.
Puma Biotechnology (NASDAQ:PBYI) last issued its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($2.07) EPS for the quarter, topping the Zacks’ consensus estimate of ($2.50) by $0.43. The company had revenue of $6.10 million for the quarter, compared to analysts’ expectations of $3.78 million. During the same period last year, the business posted ($1.11) earnings per share. equities research analysts predict that Puma Biotechnology Inc will post -8.19 EPS for the current year.
Several equities analysts recently issued reports on the company. JPMorgan Chase & Co. reaffirmed a “buy” rating and issued a $131.00 price objective on shares of Puma Biotechnology in a research report on Wednesday, October 4th. Bank of America restated a “buy” rating and issued a $135.00 price objective (up from $117.00) on shares of Puma Biotechnology in a research note on Monday, October 9th. Barclays restated a “buy” rating and issued a $122.00 price objective (up from $103.00) on shares of Puma Biotechnology in a research note on Friday, November 10th. Credit Suisse Group upped their price objective on Puma Biotechnology from $136.00 to $142.00 and gave the stock an “outperform” rating in a research note on Friday, November 10th. Finally, Royal Bank of Canada cut their price target on Puma Biotechnology from $108.00 to $92.00 and set a “sector perform” rating for the company in a research note on Friday, November 10th. They noted that the move was a valuation call. One research analyst has rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating to the company’s stock. Puma Biotechnology currently has an average rating of “Buy” and a consensus target price of $130.67.
WARNING: This story was originally published by TrueBlueTribune and is owned by of TrueBlueTribune. If you are accessing this story on another website, it was stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this story can be viewed at https://www.truebluetribune.com/2018/01/03/ameriprise-financial-inc-acquires-1443-shares-of-puma-biotechnology-inc-pbyi.html.
About Puma Biotechnology
Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.
Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.